

TEXAS CHILDREN'S HOSPITAL
EVIDENCE-BASED OUTCOMES CENTER
Bronchiolitis
Evidence-Based Guideline

Definition: Bronchiolitis is an acute inflammatory disease of the lower respiratory tract, resulting from obstruction of small airways. It is the most common lower respiratory infection in children 0-2 years in addition to being one of the most common diseases leading to hospitalization in infants less than one year of age, costing more than \$700 million annually in the United States. ^(1,2)

Pathophysiology: Bronchiolitis causes acute inflammation, edema, and necrosis of epithelial cells lining the small airways, resulting in increased mucus production and bronchospasm. Infants and children aged 2-24 months are most likely to become infected. It occurs most frequently between December and March and is usually caused by a viral infection, with Respiratory Syncytial Virus (RSV) being the most common etiology. Other common viruses include parainfluenza, influenza, adenovirus, and human metapneumovirus. ^(1,2)

Inclusion Criteria ⁽¹⁾

- Age 0-2 years with respiratory symptoms

Exclusion Criteria ⁽¹⁻³⁾

- Asthma, cystic fibrosis, bronchopulmonary dysplasia, or other chronic respiratory disease
- Recurrent wheezing
- Immunodeficiency
- Serious bacterial infection, shock, or toxic appearance
- Neuromuscular disease
- Artificial airway
- Cyanotic heart disease

Differential Diagnosis

Community-acquired pneumonia
Foreign body aspiration
Trauma/Tumors
Gastroesophageal reflux
Congenital malformations
Congenital heart disease

Diagnostic Evaluation: A clinical history and physical examination is sufficient to diagnose bronchiolitis. Infants present with symptoms of a common cold (i.e., runny nose and mild cough). Over the next few days, the cough worsens. A fever, difficulty breathing, and wheezing may develop. Symptoms, especially coughing and wheezing, can persist for 3-4 weeks, although they gradually improve during that time period. ⁽²⁾

History: Assess for ^(1,2)

- Upper Respiratory Illness (URI) with rhinorrhea
- Exposure to viral URI
- Poor fluid intake (e.g., inability to suck)
- Fever
- Personal or family history of allergy, asthma, or atopy
- Prior beta-agonist utilization
- Previous wheezing
- Passive exposure to smoking

Physical Examination

- Observe for rhinitis, tachypnea, cough, nasal flaring, shortness of breath, grunting, skin color changes, wheezing, and fever
- Obtain Clinical Respiratory Score (CRS) after nasopharyngeal suction. The CRS includes assessment of: respiratory rates, auscultation, use of accessory muscles, mental status, SpO₂, and color (see below).

Clinical Respiratory Score (CRS)			
Assess	Score 0	Score 1	Score 2
Respiratory Rate	<2 mos: <50 2-12 mos: <40 1-5 yrs: <30 >5 yrs: <20	<2 mos: 50-60 2-12 mos: 40-50 >1-5 yrs: 30-40 >5 yrs: 20-30	<2 mos: >60 2-12 mos: >50 >1-5 yrs: >40 >5 yrs: >30
Auscultation	Good air movement, scattered expiratory wheezing, loose rales/crackles	Depressed air movement, inspiratory and expiratory wheezes or rales/crackles	Diminished or absent breath sounds, severe wheezing, or rales/crackles, or marked prolonged expiration
Use of Accessory Muscles	Mild to no use of accessory muscles, mild to no retractions, no nasal flaring on inspiration	Moderate intercostal retractions, mild to moderate use of accessory muscles, nasal flaring	Severe intercostal and substernal retractions, nasal flaring
Mental Status	Normal to mildly irritable	Irritable, agitated, restless	Lethargic
Room Air SpO₂	>95%	90-95%	<90%
Color	Normal	Pale to normal	Cyanotic, dusky

(Add score from all rows to calculate total CRS score)

Critical Points of Evidence*

Evidence Supports

- History and physical should be the basis for diagnosis. (1-3) – Strong recommendation, low quality evidence
- Consider a trial dose of 0.5 mL of nebulized epinephrine to rapidly deteriorating patients only. If no effect noted from the trial dose, discontinue nebulized epinephrine. (1-14) – Weak recommendation, moderate quality evidence
- Obtain a Clinical Respiratory Score (CRS) to identify the severity of diagnosis. Pulse oximetry should be used as part of the CRS. (15-19) – Strong recommendation, low quality evidence
- Consider high flow nasal cannula therapy for patients with a CRS ≥ 7 . If the patient is rapidly deteriorating and/or cannot maintain oxygen saturation levels $\geq 90\%$ on 2 LPM of low-flow oxygen, consider high flow nasal cannula therapy. (20-23) – Weak recommendation, low quality evidence
- Consider a trial dose of albuterol only if there is a suspicion of asthma (based on historical and prior beta-agonist utilization risk factors). (1,2,7-14) – Weak recommendation, moderate quality evidence
- If patient requires supplemental oxygen, monitoring should be followed based on the oxygen weaning protocol. (1-3,24-26) – Weak recommendation, low quality evidence
- Consider withholding feedings if severe intercostal and substernal retractions, nasal flaring, and respiratory rate $>60-70$. (1, 27-29) – Weak recommendation, very low quality evidence
- Consider NG feeding for the following patients: unable to maintain hydration orally, age 2-12 months, CRS <5 , not receiving high flow oxygen, not on BiPAP or CPAP, no craniofacial abnormalities precluding NG placement. (1,4-6,30-37) – Weak recommendation, very low quality evidence
- Admit the patient if: oxygen saturation consistently $<90\%$, CRS ≥ 5 , patient requires continuous clinical assessment of airway clearance and maintenance using suctioning, patient is unable to maintain oral feedings at a level to prevent dehydration, or it is unsafe to send the patient home/poor follow-up. (38) – Strong recommendation, low quality evidence
- Discharge the patient when the following criteria are met: room air, oral feedings tolerated at a level to maintain hydration, parents can demonstrate clearance of the patient's airway using a nasal suction device, PCP follow-up appointment scheduled within 5 days, and parent discharge teaching completed. (39-41) – Strong recommendation, low quality evidence

Evidence Against

- Do not routinely administer antibiotics unless evidence of a bacterial infection. (2,3,42-45) – Strong recommendation, moderate quality evidence
- Do not routinely administer bronchodilators. (1,2, 7-14) – Strong recommendation, moderate quality evidence
- Do not use chest physiotherapy. (1-3,46,47) – Strong recommendation, high quality evidence
- Do not routinely administer systemic or inhaled corticosteroids. (1-3,12, 48-54) – Strong recommendation, moderate quality evidence
- Do not use anticholinergic drugs. (55) – Strong recommendation, moderate quality evidence
- Do not routinely administer hypertonic saline. (1,4-6,56-62) – Weak recommendation, moderate quality evidence
- Do not use high flow nasal cannula therapy for patients with a CRS <7 unless the patient is rapidly deteriorating and/or hypoxemic requiring ≥ 2 LPM of low-flow oxygen to maintain oxygen saturation levels $\geq 90\%$. (20-23) – Weak recommendation, low quality evidence
- Do not perform laboratory tests for diagnosis. (1,3,63-66) – Strong recommendation, low quality evidence
- Do not use ribavirin. (67) – Weak recommendation, moderate quality evidence
- Do not obtain a chest x-ray for diagnosis. (1,3,63,68) – Strong recommendation, low quality evidence

Evidence Lacking/Inconclusive

- Administer oxygen to maintain SpO₂ $\geq 90\%$; however, transiently lower levels may be acceptable in patients who are otherwise ready for discharge. (1) – Consensus Recommendation
- Work-up and treatment for infants <28 days with fever should be based on clinical judgment. (69-71) – Consensus recommendation
- There is insufficient evidence to address the following topic: safety of discharging patients home with oxygen. (72-76)

*NOTE: The references cited represent the entire body of evidence reviewed to make each recommendation.

Condition-Specific Elements of Clinical Management

Treatment Recommendations

- Nasopharyngeal suctioning (2,3)
 - As needed for upper airway obstruction
 - Prior to feeding
 - During assessment
 - Pre- and post-suctioning respiratory assessment

Admission Criteria (2,39)

- Oxygen saturation consistently $<90\%$
- CRS ≥ 5
- Patient requires continuous clinical assessment of airway clearance and maintenance using suctioning
- Patient is unable to maintain oral feedings at a level to prevent dehydration
- Unsafe to send home/poor follow-up

Discharge Criteria (2,3,39-41)

- Room air
- Oral feedings tolerated at a level to maintain hydration
- Parents can demonstrate he/she can clear the patient's airway using a nasal suction device
- Parent discharge teaching completed on:
 - Signs and symptoms of concern (e.g., wheezing, difficulty breathing, difficulty feeding, cough, fever)
 - Proper use of nasal suction device (bulb syringe or other commercial products) to aspirate the infant's nose
 - Proper handwashing techniques
 - Discharge care
 - Risks of passive smoking exposure

Follow-Up Care

Primary care physician follow-up appointment scheduled within 5 days

Prevent Transmission (1-3)

Transmission occurs by direct inoculation of contagious secretions from hands or from large-particle aerosols in the eyes and nose.

- Place patient on contact isolation
- Adhere to strict handwashing guidelines

Parent Teaching (1-3)

- Stress importance of strict handwashing
- Teach parents to use nasal suction device (bulb syringe or other commercial product) to aspirate the infant's nose
- Emphasize that infants should NOT be exposed to passive smoking; explore options for parents to quite smoking
- Encourage breastfeeding

Balanced Scorecard Measures

Process

- Order set utilization
- Routine testing (i.e., viral testing, chest x-rays)
- Use of non-evidence-based medications (i.e., use of oral and inhaled steroids, repeated doses of a beta-agonist, antibiotics)

Outcome


- Mean time on oxygen
- Percentage of patients who have an RRT within X hours of admission
- Percentage of patients with a change in level of care within X hours of arrival to unit
- Length of stay
- Readmission rate

TCH Evidence-Based Outcomes Center Clinical Algorithm for Bronchiolitis

Inclusion Criteria
0-24 months, wheezing with no history of asthma

Exclusion Criteria
Asthma, bronchopulmonary dysplasia, cystic fibrosis, chronic respiratory diseases, recurrent wheezing, immunodeficiency, SBI/shock, toxic appearance, neuromuscular disease, artificial airway, cyanotic heart disease

Do not delay RRT if needed at any point.



^Discharge Criteria

- Room air
- Oral feedings tolerated at a level to maintain hydration
- Parents can clear the patient's airway using a nasal suction device
- Parent understands:
 - Signs and symptoms, including: wheezing, difficulty breathing, difficulty feeding, fever
 - Proper use of nasal suction device to aspirate the patient's nose
 - Discharge care
 - Risk of passive smoking exposure
 - Proper handwashing techniques
 - PCP follow-up appointment

***Admission Criteria**

- Oxygen saturation consistently <90%
- CRS ≥5
- Patient requires continuous clinical assessment of airway clearance and maintenance using suctioning
- Patient is unable to maintain oral feedings at a level to prevent dehydration
- Unsafe to send home/poor follow-up

References

1. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. (2014). Diagnosis and management of bronchiolitis. *Pediatrics*, 134(5), e1474-e1502.
2. Cincinnati Children's Hospital. (2010). Evidence based clinical practice guideline for medical management of bronchiolitis in infants 1 year of age or less presenting with a first time episode.
3. Bronchiolitis clinical care guideline. December 2006. Children's Hospital/Kaiser/Denver Health. <http://Planettch.policies/general/index.cfm?CategoryID=9>.
4. Children's Hospital of Philadelphia. (2016). Bronchiolitis.
5. Seattle Children's Hospital (2017). Bronchiolitis.
6. Dell Children's Hospital (2017). Bronchiolitis.
7. Conway, E., Schoettker, P. J., Moore, A., Britto, M. T., Kotagal, U. R., & Rich, K. (2004). Empowering respiratory therapists to take a more active role in delivering quality care for infants with bronchiolitis. *Respiratory Care*, 49(6), 589-599.
8. Flores, G., & Horwitz, R. I. (1997). Efficacy of beta2-agonists in bronchiolitis: A reappraisal and meta-analysis. *Pediatrics*, 100(2 Pt 1), 233-239.
9. Gadomski, A. M., & Bhasale, A. L. (2006). Bronchodilators for bronchiolitis. *Cochrane Database of Systematic Reviews*(3), CD001266.
10. Hartling, L., Wiebe, N., Russell, K., Patel, H., & Klassen, T. P. (2003). A meta-analysis of randomized controlled trials evaluating the efficacy of epinephrine for the treatment of acute viral bronchiolitis. *Archives of Pediatrics and Adolescent Medicine*, 157(10), 957-964.
11. Hartling, L., Wiebe, N., Russell, K., Patel, H., & Klassen, T. P. (2004). Epinephrine for bronchiolitis. *Cochrane Database of Systematic Reviews*(1), CD003123.
12. Hartling, L., Fernandes, R. M., Bialy, L., Milne, A., Johnson, D., Plint, A., et al. (2011). Steroids and bronchodilators for acute bronchiolitis in the first two years of life: Systematic review and meta-analysis. *BMJ*, 342, d1714.
13. Skjerven, H. O., Hunderi, J. O., Brugmann-Pieper, S. K., Brun, A. C., Engen, H., Eskedal, L., et al. (2013). Racemic adrenaline and inhalation strategies in acute bronchiolitis. *New England Journal of Medicine*, 368(24), 2286-2293.
14. Wainwright, C., Altamirano, L., Cheney, M., Cheney, J., Barber, S., Price, D., et al. (2003). A multicenter, randomized, double-blind, controlled trial of nebulized epinephrine in infants with acute bronchiolitis. *New England Journal of Medicine*, 349(1), 27-35.
15. Corneli, H. M., Zorc, J. J., Holubkov, R., Bregstein, J. S., Brown, K. M., Mahajan, P., & Kuppermann, N. (2012). Bronchiolitis: Clinical characteristics associated with hospitalization and length of stay. *Pediatric Emergency Care*, 28(2), 99-103.
16. Mallory, M. D., Shay, D. K., Garrett, J., & Bordley, W. C. (2003). Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. *Pediatrics*, 111(1), e45-51.
17. Marlais, M., Evans, J., & Abrahamson, E. (2011). Clinical predictors of admission in infants with acute bronchiolitis. *Archives of Disease in Childhood*, 96(7), 648-652.
18. Destino, L., Weisgerber, M. C., Soung, P., Bakalarski, D., Yan, K., Rehborg, R., et al. (2012). Validity of respiratory scores in bronchiolitis. *Hospital Pediatrics*, 2(4), 202-209.
19. Rodl, S., Resch, B., Hofer, N., Marschitz, I., Madler, G., Eber, E., & Zobel, G. (2012). Prospective evaluation of clinical scoring systems in infants with bronchiolitis admitted to the intensive care unit. *European Journal of Clinical Microbiology & Infectious Diseases*, 31(10), 2667-2672.
20. Abboud, P. A., Roth, P. J., Skiles, C. L., Stolfi, A., & Rowin, M. E. (2012). Predictors of failure in infants with viral bronchiolitis treated with high-flow, high-humidity nasal cannula therapy*. *Pediatric Critical Care Medicine*, 13(6), e343-e349.
21. Kelly, G. S., Simon, H. K., & Sturm, J. J. (2013). High-flow nasal cannula use in children with respiratory distress in the emergency department: Predicting the need for subsequent intubation. *Pediatric Emergency Care*, 29(8), 888-892.
22. McKiernan, C., Chua, L. C., Visintainer, P. F., & Allen, H. (2010). High flow nasal cannulae therapy in infants with bronchiolitis. *Journal of Pediatrics*, 156(4), 634-638.
23. Schibler, A., Pham, T. M., Dunster, K. R., Foster, K., Barlow, A., Gibbons, K., & Hough, J. L. (2011). Reduced intubation rates for infants after introduction of high-flow nasal prong oxygen delivery. *Intensive Care Medicine*, 37(5), 847-852.
24. Ralston, S., & Hill, V. (2009). Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: A systematic review. *Journal of Pediatrics*, 155(5), 728-733.
25. Schroeder, A. R., Marmor, A. K., Pantell, R. H., & Newman, T. B. (2004). Impact of pulse oximetry and oxygen therapy on length of stay in bronchiolitis hospitalizations. *Archives of Pediatrics and Adolescent Medicine*, 158(6), 527-530.
26. Unger, S., & Cunningham, S. (2008). Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. *Pediatrics*, 121(3), 470-475.
27. Corrad, F., de La Rocque, F., Martin, E., Wollner, C., Elbez, A., Koskas, M., et al. (2013). Food intake during the previous 24 h as a percentage of usual intake: A marker of hypoxia in infants with bronchiolitis: An observational, prospective, multicenter study. *BMC Pediatrics*, 13, 6.
28. Khoshoo, V., & Edell, D. (1999). Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. *Pediatrics*, 104(6), 1389-1390.
29. Khoshoo, V., Ross, G., Kelly, B., Edell, D., & Brown, S. (2001). Benefits of thickened feeds in previously healthy infants with respiratory syncytial viral bronchiolitis. *Pediatric Pulmonology*, 31(4), 301-302.
30. de Betue, C. T., van Waardenburg, D. A., Deutz, N. E., van Eijk, H. M., van Goudoever, J. B., Luiking, Y. C., et al. (2011). Increased protein-energy intake promotes anabolism in critically ill infants with viral bronchiolitis: A double-blind randomised controlled trial. *Archives of Disease in Childhood*, 96(9), 817-822.
31. Halvorson, E. E., Chandler, N., Neiberg, R., & Ervin, S. E. (2013). Association of NPO status and type of nutritional support on weight and length of stay in infants hospitalized with bronchiolitis. *Hospital Pediatrics*, 3(4), 366-370.
32. Kugelman, A., Raibin, K., Dabbah, H., Chistyakov, I., Srugo, I., et al. Riskin, A. (2013). Intravenous fluids versus gastric-tube feeding in hospitalized infants with viral bronchiolitis: A randomized, prospective pilot study. *Journal of Pediatrics*, 162(3), 640-642 e641.
33. Oakley, E., Borland, M., Neutze, J., Acworth, J., Krieser, D., Dalziel, S., et al. (2013). Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: A randomised trial. *Lancet Respiratory Medicine*, 1(2), 113-120.
34. Oakley, E., Bata, S., Rengasamy, S., Krieser, D., Cheek, J., Jachno, K., & Babl, F. E. (2016). Nasogastric hydration in infants with bronchiolitis less than 2 months of age. *Journal of Pediatrics*, 178, 241-245 e241.
35. Sammartino, L., James, D., Goutzamanis, J., & Lines, D. (2002). Nasogastric rehydration does have a role in acute paediatric bronchiolitis. *Journal of Paediatrics and Child Health*, 38(3), 321-322.
36. Srinivasan, M., Pruitt, C., Casey, E., Dhaliwal, K., DeSanto, C., Markus, R., & Rosen, A. (2017). Quality improvement initiative to increase the use of nasogastric hydration in infants with bronchiolitis. *Hospital Pediatrics*, 7(8), 436-443.
37. National Institute for Health and Clinical Excellence. (2015). Bronchiolitis in children: Diagnosis and management.
38. Yusuf, S., Caviness, A. C., & Adekunle-Ojo, A. O. (2012). Risk factors for admission in children with bronchiolitis from pediatric emergency department observation unit. *Pediatric Emergency Care*, 28(11), 1132-1135.
39. Cunningham, S., & McMurray, A. (2012). Observational study of two oxygen saturation targets for discharge in bronchiolitis. *Archives of Disease in*

- Childhood*, 97(4), 361-363.
40. Mansbach, J. M., Clark, S., Christopher, N. C., LoVecchio, F., Kunz, S., Acholonu, U., & Camargo, C. A., Jr. (2008). Prospective multicenter study of bronchiolitis: Predicting safe discharges from the emergency department. *Pediatrics*, 121(4), 680-688.
 41. Sandweiss, D. R., Corneli, H. M., & Kadish, H. A. (2010). Barriers to discharge from a 24-hour observation unit for children with bronchiolitis. *Pediatric Emergency Care*, 26(12), 892-896.
 42. McCallum, G. B., Morris, P. S., & Chang, A. B. (2012). Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. *Cochrane Database of Systematic Reviews*, 12, CD009834.
 43. Pinto, L. A., Pitrez, P. M., Luisi, F., de Mello, P. P., Gerhardt, M., Ferlini, R., et al. (2012). Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: A randomized, double-blinded, and placebo-controlled clinical trial. *Journal of Pediatrics*, 161(6), 1104-1108.
 44. Spurling, G. K., Fonseka, K., Doust, J., & Del Mar, C. (2007). Antibiotics for bronchiolitis in children. *Cochrane Database of Systematic Reviews*(1), CD005189.
 45. Spurling, G. K., Doust, J., Del Mar, C. B., & Eriksson, L. (2011). Antibiotics for bronchiolitis in children. *Cochrane Database of Systematic Reviews*(6), CD005189.
 46. Perrotta, C., Ortiz, Z., & Roque, M. (2007). Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. *Cochrane Database of Systematic Reviews*(1), CD004873.
 47. Roque i Figuls, M., Gine-Garriga, M., Granados Rugeles, C., & Perrotta, C. (2012). Chest physiotherapy for acute bronchiolitis in paediatric patients between 0 and 24 months old. *Cochrane Database of Systematic Reviews*(2), CD004873.
 48. Alansari, K., Sakran, M., Davidson, B. L., Ibrahim, K., Alrefai, M., & Zakaria, I. (2013). Oral dexamethasone for bronchiolitis: A randomized trial. *Pediatrics*, 132(4), e810-816.
 49. Schuh, S., Coates, A. L., Dick, P., Stephens, D., Lalani, A., Nicota, E., et al. (2008). A single versus multiple doses of dexamethasone in infants wheezing for the first time. *Pediatric Pulmonology*, 43(9), 844-850.
 50. Plint, A. C., Johnson, D. W., Patel, H., Wiebe, N., Correll, R., Brant, R., et al. (2009). Epinephrine and dexamethasone in children with bronchiolitis. *New England Journal of Medicine*, 360(20), 2079-2089.
 51. Blom, D., Ermers, M., Bont, L., van Aalderen, W. M., & van Woensel, J. B. (2007). Inhaled corticosteroids during acute bronchiolitis in the prevention of post-bronchiolitic wheezing. *Cochrane Database of Systematic Reviews*(1), CD004881.
 52. Corneli, H. M., Zorc, J. J., Mahajan, P., Shaw, K. N., Holubkov, R., Reeves, S. D., et al. (2007). A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. *New England Journal of Medicine*, 357(4), 331-339.
 53. Garrison, M. M., Christakis, D. A., Harvey, E., Cummings, P., & Davis, R. L. (2000). Systemic corticosteroids in infant bronchiolitis: A meta-analysis. *Pediatrics*, 105(4), E44.
 54. Sumner, A., Coyle, D., Mitton, C., Johnson, D. W., Patel, H., Klassen, T. P., et al. (2010). Cost-effectiveness of epinephrine and dexamethasone in children with bronchiolitis. *Pediatrics*, 126(4), 623-631.
 55. Everard, M. L., Bara, A., Kurian, M., Elliott, T. M., Ducharme, F., & Mayowe, V. (2005). Anticholinergic drugs for wheeze in children under the age of two years. *Cochrane Database of Systematic Reviews*(3), CD001279.
 56. Angoulvant, F., Belletre, X., Milcent, K., Teglas, J. P., Claudet, I., Gras Le Guen, C., et al. (2017). Effect of nebulized hypertonic saline treatment in emergency departments on the hospitalization rate for acute bronchiolitis: A randomized clinical trial. *JAMA Pediatrics*, 171(8), e171333.
 57. Badgett, R. G., openMetaAnalysis Contributors. Hypertonic saline for bronchiolitis: A living systematic review. Available at: <https://openmetaanalysis.github.io/Hypertonic-Saline-for-Bronchiolitis/> Accessed November 24, 2017. Contributions archived at: <https://github.com/badgettrr>
 58. Brooks, C. G., Harrison, W. N., & Ralston, S. L. (2016). Association between hypertonic saline and hospital length of stay in acute viral bronchiolitis: A reanalysis of 2 meta-analyses. *JAMA Pediatrics*, 170(6), 577-584.
 59. Chen, Y. J., Lee, W. L., Wang, C. M., & Chou, H. H. (2014). Nebulized hypertonic saline treatment reduces both rate and duration of hospitalization for acute bronchiolitis in infants: An updated meta-analysis. *Pediatric Neonatology*, 55(6), 431-438.
 60. Maguire, C., Cantrill, H., Hind, D., Bradburn, M., & Everard, M. L. (2015). Hypertonic saline (HS) for acute bronchiolitis: Systematic review and meta-analysis. *BMC Pulmonary Medicine*, 15, 148.
 61. Zhang, L., Mendoza-Sassi, R. A., Wainwright, C., & Klassen, T. P. (2013). Nebulised hypertonic saline solution for acute bronchiolitis in infants. *Cochrane Database of Systematic Reviews*(7), CD006458.
 62. Zhang, L., Mendoza-Sassi, R. A., Klassen, T. P., & Wainwright, C. (2015). Nebulized hypertonic saline for acute bronchiolitis: A systematic review. *Pediatrics*, 136(4), 687-701.
 63. Bordley, W. C., Viswanathan, M., King, V. J., Sutton, S. F., Jackman, A. M., Sterling, L., & Lohr, K. N. (2004). Diagnosis and testing in bronchiolitis: A systematic review. *Archives of Pediatrics and Adolescent Medicine*, 158(2), 119-126.
 64. Purcell, K., & Fergie, J. (2007). Lack of usefulness of an abnormal white blood cell count for predicting a concurrent serious bacterial infection in infants and young children hospitalized with respiratory syncytial virus lower respiratory tract infection. *Pediatric Infectious Disease Journal*, 26(4), 311-315.
 65. Tarini, B. A., Garrison, M. M., & Christakis, D. A. (2007). Institutional variation in ordering complete blood counts for children hospitalized with bronchiolitis. *Journal of Hospital Medicine*, 2(2), 69-73.
 66. Luu, R., DeWitt, P. E., Reiter, P. D., Dobyms, E. L., & Kaufman, J. (2013). Hyponatremia in children with bronchiolitis admitted to the pediatric intensive care unit is associated with worse outcomes. *Journal of Pediatrics*, 163(6), 1652-1656, e1651.
 67. Viswanathan, M., King, V. J., Bordley, C., Honeycutt, A. A., Wittenborn, J., Jackman, A. M., et al. (2003). Management of bronchiolitis in infants and children. *Evidence Report/Technology Assessment (Summary)*(69), 1-5. In: AHRQ Evidence Report Summaries. Rockville (MD): Agency for Healthcare Research and Quality (US); 1998-2005. 69.
 68. Swingler, G. H., Hussey, G. D., & Zwarenstein, M. (1998). Randomised controlled trial of clinical outcome after chest radiograph in ambulatory acute lower-respiratory infection in children. *Lancet*, 351(9100), 404-408.
 69. Levine, D. A., Platt, S. L., Dayan, P. S., Macias, C. G., Zorc, J. J., Krief, W., et al. (2004). Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. *Pediatrics*, 113(6), 1728-1734.
 70. Kuppermann, N., Bank, D. E., Walton, E. A., Senac, M. O., Jr., & McCaslin, I. (1997). Risks for bacteremia and urinary tract infections in young febrile children with bronchiolitis. *Archives of Pediatrics and Adolescent Medicine*, 151(12), 1207-1214.
 71. Yarden-Bilavsky, H., Ashkenazi-Hoffnung, L., Livni, G., Amir, J., & Bilavsky, E. (2011). Month-by-month age analysis of the risk for serious bacterial infections in febrile infants with bronchiolitis. *Clinical Pediatrics*, 50(11), 1052-1056.
 72. Bajaj, L., Turner, C. G., & Bothner, J. (2006). A randomized trial of home oxygen therapy from the emergency department for acute bronchiolitis. *Pediatrics*, 117(3), 633-640.
 73. Gauthier, M., Vincent, M., Morneau, S., & Chevalier, I. (2012). Impact of home oxygen therapy on hospital stay for infants with acute bronchiolitis. *European Journal of Pediatrics*, 171(12), 1839-1844.
 74. Halstead, S., Roosevelt, G., Deakynne, S., & Bajaj, L. (2012). Discharged on supplemental oxygen from an emergency department in patients with bronchiolitis. *Pediatrics*, 129(3), e605-610.

75. Sandweiss, D. R., Mundorff, M. B., Hill, T., Wolfe, D., Greene, T., Andrews, S., & Glasgow, T. S. (2013). Decreasing hospital length of stay for bronchiolitis by using an observation unit and home oxygen therapy. *JAMA Pediatrics*, *167*(5), 422-428.
76. Tie, S. W., Hall, G. L., Peter, S., Vine, J., Verheggen, M., Pascoe, E. M., et al. (2009). Home oxygen for children with acute bronchiolitis. *Archives of Disease in Childhood*, *94*(8), 641-643.

Clinical Standards Preparation

This clinical standard was prepared by the Evidence-Based Outcomes Center (EBOC) team in collaboration with content experts at Texas Children's Hospital. Development of this clinical standard supports the TCH Quality and Patient Safety Program initiative to promote clinical standards and outcomes that build a culture of quality and safety within the organization.

Bronchiolitis Content Expert Team

Susan Engleman, RN, Nursing
 Khoulood Fakhoury, MD, Pulmonary Medicine
 William Hogan, MD, Texas Children's Pediatrics
 Suzanne Iniguez, RT, Respiratory Care
 Julia Lawrence, RT, Respiratory Care
 Su Rin Lee, PharmD, Pharmacy
 Huay-ying Lo, MD, Pediatric Hospital Medicine
 Mona McPherson, MD, Critical Care
 Sarah Meskill, MD, Emergency Medicine
 Robert Moore, MD, Pulmonary Medicine
 Brent Mothner, MD, Pediatric Hospital Medicine
 Kristen Mullins, RN, Nursing
 Elizabeth Spoede, MS, RD, CSP, LD, Food and Nutrition Services
 Joyee Vachani, MD, Pediatric Hospital Medicine

EBOC Team

Development Process

This clinical standard was developed using the process outlined in the EBOC Manual. The literature appraisal documents the following steps:

1. Review Preparation
 - PICO questions established
 - Evidence search confirmed with content experts
2. Review of Existing External Guidelines
 - American Academy of Pediatrics Diagnosis and Management of Bronchiolitis (2014), National Institute for Health and Clinical Excellence Bronchiolitis in Children: Diagnosis and Management (2015), Children's Hospital/Kaiser/Denver Health Bronchiolitis (2006), Cincinnati Children's Hospital Bronchiolitis (2010), Children's Hospital of Philadelphia Bronchiolitis (2016), Seattle Children's Hospital Bronchiolitis (2017), Dell Children's Hospital Bronchiolitis (2017)
3. Literature Review of Relevant Evidence
 - Searched: PubMed, CINAHL, SUM search, Google Scholar
4. Critically Analyze the Evidence
 - 22 systematic reviews/meta-analyses, 17 randomized controlled trials, and 30 nonrandomized studies
5. Summarize the Evidence
 - Materials used in the development of the clinical standard, literature appraisal, and any order sets are maintained in a bronchiolitis evidence-based review manual within EBOC.

Evaluating the Quality of the Evidence

Published clinical guidelines were evaluated for this review using the **AGREE II** criteria. The summary of these guidelines are included in the literature appraisal. AGREE II criteria evaluate Guideline Scope and Purpose, Stakeholder Involvement, Rigor of Development, Clarity and Presentation, Applicability, and Editorial Independence using a 4-point Likert scale. The higher the score, the more comprehensive the guideline.

This clinical standard specifically summarizes the evidence *in support of* or *against* specific interventions and identifies where evidence is *lacking/inconclusive*. The following categories describe how research findings provide support for treatment interventions. **"Evidence Supports"** provides evidence to support an intervention. **"Evidence Against"** provides evidence against an intervention. **"Evidence Lacking/Inconclusive"** indicates there is insufficient evidence to support or refute an intervention and no conclusion can be drawn *from the evidence*.

The **GRADE** criteria were utilized to evaluate the body of evidence used to make practice recommendations. The table below defines how the quality of the evidence is rated and how a strong versus weak recommendation is established. The literature appraisal reflects the critical points of evidence.

Recommendation	
STRONG	Desirable effects clearly outweigh undesirable effects or vice versa
WEAK	Desirable effects closely balanced with undesirable effects
Quality	Type of Evidence
High	Consistent evidence from well-performed RCTs or exceptionally strong evidence from unbiased observational studies
Moderate	Evidence from RCTs with important limitations (e.g., inconsistent results, methodological flaws, indirect evidence, or imprecise results) or unusually strong evidence from unbiased observational studies
Low	Evidence for at least 1 critical outcome from observational studies, RCTs with serious flaws or indirect evidence
Very Low	Evidence for at least 1 critical outcome from unsystematic clinical observations or very indirect evidence

Recommendations

Practice recommendations were directed by the existing evidence and consensus amongst the content experts. Patient and family preferences were included when possible. The Content Expert Team and EBOC team remain aware of the controversies in the management of bronchiolitis in children. When evidence is lacking, options in care are provided in the clinical standard and the accompanying order sets (if applicable).

Approval Process

Clinical standards are reviewed and approved by hospital committees as deemed appropriate for its intended use. Clinical standards are reviewed as necessary within EBOC at Texas Children's Hospital. Content Expert Teams are involved with every review and update.

Disclaimer

Practice recommendations are based upon the evidence available at the time the clinical standard was developed. Clinical standards (guidelines, summaries, or pathways) do not set out the standard of care and are not intended to be used to dictate a course of care. Each physician/practitioner should use his or her independent judgment in the management of any specific patient and is responsible, in consultation with the patient and/or the patient's family, to make the ultimate judgment regarding care.

Permission of Use

All content on this website is protected by copyright law. Unauthorized use, reproduction, or distribution of any part of this work is prohibited without written permission from Texas Children's Hospital. Please contact eboc@texaschildrens.org to obtain necessary permissions for usage of the materials on this website.

Version History

Date	Comments
Dec 2008	Originally completed
Jan 2010	Updated
Mar 2014	Updated
Jul 2016	Minor revisions
Feb 2017	Algorithm edits
Feb 2018	Changed hypertonic saline recommendation and CRS cutoff for HFNC therapy; added option for feedings via NG tube
Oct 2021	Reaffirmed
Dec 2023	Minor Algorithm Edit